CG Oncology | 4: Statement of changes in beneficial ownership of securities-Director Song Hong Fang
CG Oncology | 144: Notice of proposed sale of securities pursuant to Rule 144
CG Oncology | 144: Notice of proposed sale of securities pursuant to Rule 144
CG Oncology | 144: Notice of proposed sale of securities pursuant to Rule 144
CG Oncology | 144: Notice of proposed sale of securities pursuant to Rule 144
CG Oncology | 10-Q: Quarterly report
CG Oncology | 8-K: CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
CG Oncology | SC 13G: Statement of acquisition of beneficial ownership by individuals-SONG, Hong Fang(8.3%),Healthcare Seed Limited(7.4%), etc.
CG Oncology | 8-K: Current report
CG Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Patterson Joshua F.
CG Oncology | 3: Initial statement of beneficial ownership of securities-Officer Patterson Joshua F.
CG Oncology | 8-K: CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
CG Oncology | 10-Q: Quarterly report
CG Oncology | 8-K: Current report
CG Oncology | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Xiangmin Cui(8.2%),Decheng Capital Global Life Sciences Fund IV, L.P.(7.4%), etc.
CG Oncology | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-10% Owner Decheng Capital Global Life Sciences Fund IV, L.P.
CG Oncology | 10-K: FY2023 Annual Report
CG Oncology | SC 13G: Statement of acquisition of beneficial ownership by individuals-Kissei Pharmaceutical Co., Ltd.(5.3%)
CG Oncology | 8-K: Current report
CG Oncology | SC 13G: Statement of acquisition of beneficial ownership by individuals-TCG Crossover GP I, LLC(5.4%),TCG Crossover Fund I, L.P.(5.4%), etc.
No Data
No Data